Evozyne has announced the closing of an $81 million series B investment round that will fund the biotech’s generative AI-powered drug discovery platform and product development.
Across the global life sciences supply chain, data, digitalization, automation, and artificial intelligence are driving the most innovation, according to a new survey from CRB.
LabGenius, a company focused on machine learning (ML) for antibody discovery, has presented key data in a poster presentation at the Single-Domain Antibodies 2023 Meeting.
Optibrium, a developer of software and AI solutions for drug discovery, has acquired BioPharmics in a view to expand its 3D drug design and modelling offering.
GEDiCube is joining NVIDIA Inception, a program which guides start-ups by providing access to cutting-edge technology, technical resources, and venture capitalists.
Unquestionably, the buzzword of 2023 is artificial intelligence (AI). From ChatGPT-4 preparing to revolutionize online research to IBM’s project debater engaging humans in live debates, it’s clear that we stand at the dawn of a new era of assistive and...
Following its latest funding round, Rosa Biotech has announced plans to accelerate development of its bio-sensing technology, designed to enable cost effective screening of a range of diseases with high accuracy at an early stage.
BenevolentAI, a clinical-stage AI development company, has announced the successful delivery of its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS), BEN-34712.
LabGenius, which uses machine learning (ML) for antibody discovery, has presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) annual meeting.
Moderna will explore next generation technologies - including quantum computing and artificial intelligence - to advance and accelerate mRNA research via a new partnership with IBM.
California based, Theragent, a cell therapy CDMO, has signed a multi-year exclusive contract with Insight68, an AI-driven software provider that aims to digitalize and streamline the cell therapy manufacturing process.
German mRNA pioneer BioNTech will acquire InstaDeep, an artificial intelligence and machine learning specialist, for around £362m ($439m): pledging to incorporate rapidly evolving AI capabilities into its research, drug discovery, manufacturing and deployment...
BigHat Biosciences, a US biotech with a machine learning-guided antibody discovery and development platform, has announced a collaboration with Merck to apply its technology to design candidates for up to three drug discovery programs.
Sanofi and Insilico Medicine have announced a multi-year, multi-target strategic research collaboration: leveraging Insilico’s ‘Pharma.AI’ platform to advance drug development for up to six new targets.
Merck (MSD outside the US and Canada) is welcoming applications from early-stage biomedical start-ups for its newly launched Merck Digital Sciences Studio (MDSS): which seeks to support technologies for drug discovery and development.
Abu Dhabi-based entities, the sovereign wealth fund, Mubadala Investment Company, and AI and cloud computing specialist, G42, are to set up a biopharma campus there; the move is aimed at bolstering biopharma linked innovation, R&D and manufacturing...
Absci Corporation says its newly opened campus in Vancouver, Washington, in the US, expands its ability to accelerate discovery and development of biologic drugs.
AION Labs, a ‘first-of-its-kind’ innovation lab that will create and adopt AI technology to transform the process of drug discovery and development, has officially launched this month.